SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Shah Ninah))
 

Sökning: (WFRF:(Shah Ninah)) > Bortezomib-Based In...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006299naa a2200673 4500
001oai:DiVA.org:uu-441708
003SwePub
008210505s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:146292024
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4417082 URI
0247 a https://doi.org/10.1016/j.jtct.2020.11.0182 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1462920242 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Cornell, Robert F.u AbbVie, N Chicago, IL USA4 aut
2451 0a Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden
264 1b Elsevier,c 2021
338 a print2 rdacarrier
520 a The benefits of pre-transplant induction chemotherapy in light chain (AL) amyloidosis, a low burden plasma cell (PC) neoplasm associated with multiorgan dysfunction, is debatable, although with the availability of bortezomib, this approach is being increasingly pursued. We analyzed the outcomes of AL amyloidosis patients undergoing autologous hematopoietic cell transplant between 2014 and 2018 that were reported to the Center for International Blood and Marrow Transplant Research database. Of 440 patients, 294 received bortezomib-based induction, and 146 received no induction. Patients receiving induction had greater PC burden compared to no induction (PC 10% or more, 39% versus 11%; P < .01). At 2 years, the induction group compared to no induction had lower relapse/progression: 13% (9% to 18%) versus 23% (16% to 32%) (P = .02); better progression-free survival (PFS): 82% (77% to 87%) versus 69% (61% to 77%) (P < .01); and similar overall survival (OS): 92% (88% to 95%) versus 89% (84% to 94%) (P = .22), findings that were confirmed on multivariate analysis. A subset analysis limited to patientswith <10% PC also showed superior relapse/progression (hazard ratio [HR],.43; 95% confidence interval [CI],.24 to.78; P < .01) and PFS (HR,.43; 95% CI,.26 to .72; P < .01) for induction compared to no induction. Thus, we conclude that pre-transplant bortezomib-based induction was associated with improved relapse/progression and PFS in AL amyloidosis. Longer survival follow-up is warranted, as OS was excellent in both cohorts at 2 years.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Bone marrow transplant
653 a Hem malignancies
653 a Myeloma
7001 a Fraser, Raphaelu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA4 aut
7001 a Costa, Lucianou Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA4 aut
7001 a Goodman, Staceyu Vanderbilt Univ, Med Ctr, Nashville, TN USA4 aut
7001 a Estrada-Merly, Noelu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut
7001 a Lee, Cindyu Royal Adelaide Hosp, Adelaide, SA, Australia4 aut
7001 a Hildebrandt, Gerhardu Univ Kentucky, Markey Canc Ctr, Lexington, KY USA4 aut
7001 a Gergis, Usamau Thomas Jefferson Univ, Dept Med Oncol, Div Hematol Malignancies, Philadelphia, PA 19107 USA4 aut
7001 a Farhadfar, Noshau Univ Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA4 aut
7001 a Freytes, César O.u Texas Transplant Inst, San Antonio, TX USA4 aut
7001 a Kamble, Rammurti T.u Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA4 aut
7001 a Krem, Maxwellu Univ Kentucky, Markey Canc Ctr, Lexington, KY USA4 aut
7001 a Kyle, Robert A.u Mayo Clin Rochester, Rochester, MN USA4 aut
7001 a Lazarus, Hillard M.u Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA4 aut
7001 a Marks, David I.u Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England4 aut
7001 a Meehan, Kennethu Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA4 aut
7001 a Patel, Sagar S.u Univ Utah, Blood & Marrow Transplant Program, Salt Lake City, UT USA4 aut
7001 a Ramanathan, Muthalaguu UMass Mem Med Ctr, Dept Med, Div Hematol & Oncol, Worcester, MA USA4 aut
7001 a Olsson, Richard F.u Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden4 aut0 (Swepub:uu)riols677
7001 a Wagner, John L.u Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA4 aut
7001 a Kumar, Shajiu Mayo Clin Rochester, Rochester, MN USA4 aut
7001 a Qazilbash, Muzaffar H.u MD Anderson Canc Ctr, Houston, TX USA4 aut
7001 a Shah, Ninahu Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA4 aut
7001 a Hari, Parameswaranu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut
7001 a D'Souza, Anitau Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut
7102 a AbbVie, N Chicago, IL USAb Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA4 org
7730 t Transplantation and Cellular Therapyd : Elsevierg 27:3, s. 264.e1-264.e7q 27:3<264.e1-264.e7x 2666-6375x 2666-6367
8564 u https://doi.org/10.1016/j.jtct.2020.11.018
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-441708
8564 8u https://doi.org/10.1016/j.jtct.2020.11.018
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:146292024

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy